


PHARMACEUTICAL 2022



Pacira BioSciences Inc. Rank 92 of 475







PHARMACEUTICAL 2022



Pacira BioSciences Inc. Rank 92 of 475



The relative strengths and weaknesses of Pacira BioSciences Inc. are analyzed with respect to the market average, including all of its competitors. We analyzed all variables having an effect on the Economic Capital Ratio.

The greatest strength of Pacira BioSciences Inc. compared to the market average is the variable Net Income, increasing the Economic Capital Ratio by 186% points. The greatest weakness of Pacira BioSciences Inc. is the variable Other Liabilities, reducing the Economic Capital Ratio by 58% points.

The company's Economic Capital Ratio, given in the ranking table, is 57%, being 333% points above the market average of -276%.

Input Variable	Value in 1000 USD
Assets, Current	866,048
Cost of Goods Sold	140,255
Intangible Assets	769,143
Liabilities, Current	521,118
Liabilities, Non-Current	91,699
Other Assets	251,761
Other Compr. Net Income	-151
Other Expenses	70,888
Other Liabilities	732,128
Other Net Income	-33,520
Property and Equipment	188,401
Research and Development	55,545
Revenues	541,533
Selling, General and Administrative Expense	199,345

Output Variable	Value in 1000 USD
Assets	2,075,353
Liabilities	1,344,945
Expenses	466,033
Stockholders Equity	730,408
Net Income	41,980
Comprehensive Net Income	41,904
Economic Capital Ratio	57%

